Evidence map›Paper›PMID 40976792›Full record

SynthesisCardiovascular and interventional radiology2025

Percutaneous Sclerotherapy Versus Transarterial Chemoembolization for Giant Hepatic Hemangiomas: A Systematic Review and Meta-analysis.

Alperen Elek, Ahmet Günkan, Victor Arthur Ohannesian, Lucas Lima Mendes, Emin Albayrak, Isa Cam, Ismail Oran, Jack Hannallah, Gregory Woodhead, Shamar Young

Abstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Publisher
In one paragraph

Synthesis in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alperen ElekDepartment of Interventional Radiology, Faculty of Medicine, Ege University, Izmir, Turkey.ORCID http://orcid.org/0000-0001-5414-6548
Ahmet GünkanDivision of Vascular and Interventional Radiology, Department of Radiology and Imaging Sciences, University of Arizona, Tucson, AZ, USA. gunkanahmet@gmail.com.ORCID http://orcid.org/0000-0002-6236-5633
Victor Arthur OhannesianCenter of Interventional Radiology, Albert Einstein Israeli Faculty of Health Sciences (FICSAE), São Paulo, Brazil.ORCID http://orcid.org/0009-0007-8742-1818
Lucas Lima MendesDepartment of Medicine, University of Taubaté, Taubaté, São Paulo, Brazil.ORCID http://orcid.org/0009-0004-1828-5689
Emin AlbayrakDepartment of Radiology, UT Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0003-2161-3060
Isa CamDepartment of Radiology, Faculty of Medicine, Kocaeli University, Kocaeli, Türkiye.
Ismail OranDepartment of Interventional Radiology, Faculty of Medicine, Ege University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-3546-7773
Jack HannallahDivision of Vascular and Interventional Radiology, Department of Radiology and Imaging Sciences, University of Arizona, Tucson, AZ, USA.
Gregory WoodheadDivision of Vascular and Interventional Radiology, Department of Radiology and Imaging Sciences, University of Arizona, Tucson, AZ, USA.
Shamar YoungDivision of Vascular and Interventional Radiology, Department of Radiology and Imaging Sciences, University of Arizona, Tucson, AZ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to systematically evaluate the efficacy and safety of different bleomycin administration routes for treating GHHs, with a subgroup analysis comparing Transarterial chemoembolization (TACE) and percutaneous sclerotherapy (PS).

methodsA systematic literature search was conducted in MEDLINE, Scopus, and Web of Science from inception through May 6, 2025. Studies included reporting clinical and radiological outcomes after PS and TACE for GHHs (≥ 4 cm). Primary outcomes included technical success (complete and accurate application as predetermined in the study protocol), safety outcomes, clinical (symptom relief without additional intervention), and radiological success (≥ 50% size reduction and/or lack of enhancement on follow-up imaging). The outcomes were analyzed using a random-effects meta-analysis 106 1586.

resultsA total of 17 studies, including 1692 patients (1586 treated with TACE and 106 with PS) and 1825 GHHs, were included. Among these, 13 studies assessed TACE, and four studies evaluated PS. The overall technical success rate was 100%, with pooled clinical and radiological success rates of 96.93% and 81.75%, respectively. In subgroup analyses, both TACE and PS achieved 100% technical success. TACE showed slightly higher clinical success, at 99.9%, compared to PS at 89.73%, although the difference was not statistically significant (p = 0.15). Radiological success was comparable (TACE: 81.9%, PS: 81.29%). Major complications were rare (0.27%, 95% CI: 0-0.55%). No significant differences were observed in major complication rates (TACE: 0.26%, PS: 0.85%, p = 0.67), total complications (p = 0.48), or procedure-related morbidity.

conclusionBoth TACE and PS are effective treatments for GHHs, with PS showing a lower systemic complication rate.

Indexed as

BleomycinChemoembolization, TherapeuticHemangiomaLiver NeoplasmsSclerotherapyAntibiotics, AntineoplasticHumansTreatment OutcomeAntibiotics, AntineoplasticBleomycinBleomycinGiant hepatic hemangiomasPercutaneous sclerotherapy (PS)Transarterial chemoembolization (TACE)

Identifiers

PMID40976792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.